Solventum Corporation $SOLV Shares Sold by Truvestments Capital LLC

Key Points

• Truvestments Capital LLC significantly reduced its stake in Solventum Corporation by 82.8%, selling 3,583 shares and retaining only 742 shares, with a valuation of $56,000.
• Solventum reported quarterly earnings of $1.69 per share, exceeding analysts' expectations of $1.45 and demonstrating year-over-year revenue growth of 3.8%.
• Recent analyst ratings varied, with Morgan Stanley upgrading Solventum from "equal weight" to "overweight" and raising the target price from $80 to $103, while the stock currently has an average target price of $85.75.

Truvestments Capital LLC trimmed its stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 82.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 742 shares of the company's stock after selling 3,583 shares during the quarter. Truvestments Capital LLC's holdings in Solventum were worth $56,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Marshall Wace LLP bought a new position in shares of Solventum during the fourth quarter worth about $378,000. Price T Rowe Associates Inc. MD grew its position in shares of Solventum by 0.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 200,542 shares of the company's stock worth $13,249,000 after acquiring an additional 770 shares in the last quarter. Quarry LP bought a new stake in shares of Solventum in the 4th quarter valued at approximately $62,000. Beacon Pointe Advisors LLC increased its holdings in shares of Solventum by 8.3% in the 4th quarter. Beacon Pointe Advisors LLC now owns 9,091 shares of the company's stock valued at $601,000 after acquiring an additional 694 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Solventum by 21.5% during the 4th quarter. Northern Trust Corp now owns 1,749,301 shares of the company's stock valued at $115,559,000 after acquiring an additional 309,077 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Wells Fargo & Company increased their target price on shares of Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Wall Street Zen upgraded Solventum from a "buy" rating to a "strong-buy" rating in a research note on Monday. KeyCorp started coverage on Solventum in a research report on Friday, June 6th. They set a "sector weight" rating on the stock. Piper Sandler restated an "overweight" rating and set a $94.00 price objective (up previously from $87.00) on shares of Solventum in a research report on Friday, August 8th. Finally, Morgan Stanley raised Solventum from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $85.75.

Solventum Stock Performance

Solventum stock traded down $0.57 during midday trading on Wednesday, reaching $71.26. 481,010 shares of the stock traded hands, compared to its average volume of 1,076,896. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The firm has a fifty day moving average price of $73.70 and a two-hundred day moving average price of $72.80. The firm has a market cap of $12.35 billion, a price-to-earnings ratio of 32.98, a PEG ratio of 1.77 and a beta of 0.53. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. The firm had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. Solventum's revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.